PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Teiluf, K.* ; Seidl, C.* ; Blechert, B.* ; Gaertner, F.C.* ; Gilbertz, K.P.* ; Fernandez, V.* ; Bassermann, F.* ; Endell, J.* ; Boxhammer, R.* ; Leclair, S.* ; Vallon, M.* ; Aichler, M. ; Feuchtinger, A. ; Bruchertseifer, F.* ; Morgenstern, A.* ; Essler, M.*

α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.

Oncotarget 6, 4692-4703 (2015)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
In spite of development of molecular therapeutics, multiple myeloma (MM) is fatal in most cases. CD38 is a promising target for selective treatment of MM. We tested radioimmunoconjugates consisting of the α-emitter 213Bi coupled to an anti-CD38 MAb in preclinical treatment of MM. Efficacy of 213Bi-anti-CD38-MAb was assayed towards different MM cell lines with regard to induction of DNA double-strand breaks, induction of apoptosis and initiation of cell cycle arrest. Moreover, mice bearing luciferase-expressing MM xenografts were treated with 213Bi-anti-CD38-MAb. Therapeutic efficacy was monitored by bioluminescence imaging, overall survival and histology. 213Bi-anti-CD38-MAb treatment induced DNA damage which did not result in activation of the G2 DNA-damage-response checkpoint, but instead in mitotic arrest and subsequent mitotic catastrophe. The anti-tumor effect of 213Bi-anti-CD38-MAb correlated with the expression level of CD38 in each MM cell line. In myeloma xenografts, treatment with 213Bi-anti-CD38-MAb suppressed tumor growth via induction of apoptosis in tumor tissue and significantly prolonged survival compared to controls. The major organ systems did not show any signs of 213Bi-induced toxicity. Preclinical treatment of MM with 213Bi-anti-CD38-MAb turned out as an effective therapeutic option.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.359
1.250
36
36
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Anti-cd38-mab ; Cell Death ; Multiple Myeloma Xenograft Model ; Opm2 Cells ; Radioimmunotherapy ; α-emitter 213bi; Randomized Controlled-trial; Stem-cell Transplantation; Monoclonal-antibody; Bone-marrow; Particle Immunotherapy; Therapy; Lymphoma; Leukemia; Radioimmunoconjugate; Inhibitors
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2015
ISSN (print) / ISBN 1949-2553
e-ISSN 1949-2553
Zeitschrift OncoTarget
Quellenangaben Band: 6, Heft: 7, Seiten: 4692-4703 Artikelnummer: , Supplement: ,
Verlag Impact Journals LLC
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pathology (PATH)
Research Unit Analytical Pathology (AAP)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-500300-001
G-500390-001
PubMed ID 25576914
WOS ID WOS:000352792000012
Scopus ID 84925013617
DOI 10.18632/oncotarget.2986
Erfassungsdatum 2015-01-14
[➜Korrektur melden]